OVERVIEW

The Latest Update on Metachromatic Leukodystrophy: Screening, Diagnosis, and Emerging Treatments to Improve Quality of Life of Patients is organized by CME Outfitters, LLC.

Premiere Date: 18-10-2022
Credit Expiration Date: 18-10-2023

Description:
Statement of Need:
Current and emerging therapies and treatment approaches can offer symptom relief and improved quality of life for patients with metachromatic leukodystrophy (MLD). But given MLD's rarity and healthcare professionals' lack of familiarity with the disease and its treatment, diagnosis is often inaccurate or delayed, negatively impacting outcomes. 

During this 90-minute enduring material, expert panelists will discuss biomarkers that identify patients at the pre-symptomatic phase of the disease and share knowledge about caring for patients with MLD.

Learning Objectives:
At the end of this CME/CE activity, participants should be able to:
• Review the impact of diagnostic delay and misdiagnosis on patients with MLD.
• Indicate strategies for identifying patients with MLD at the pre-symptomatic phase of the disease.
• Implement early screening for patients with suspected MLD based on symptoms and clinical presentations.
• Evaluate the efficacy and safety of emerging therapies for MLD.

TARGET AUDIENCE

PhysicianNursingPharmacistPhysician AssistantEndocrinologistsPrimary Care PhysicianNeurologistsNursesInternal MedicineMedical GeneticistsPediatricsNurse Practitioners

SPECIALITIES

EndocrinologyNeurology

RELATED ONLINE COURSES

Illinois Nurse Practitioners State Board required courses bundle
Jul 14, 2021 - Jun 22, 2025 | Webcast
State required course for Illinois
4 AMA PRA Category 1 Credit™ ...
More actions
US$470
Ohio Nurse Practitioners State Board required courses bundle
Jul 14, 2021 - Jun 22, 2025 | Webcast
State required course for Ohio
12 Contact Hours
More actions
US$470
Alaska Nurse Practitioners State Board required courses bundle
Jul 14, 2021 - May 23, 2025 | Webcast
State required course for Alaska
4 AMA PRA Category 1 Credit™ ...
More actions
US$440